Chronic Low Back Pain Clinical Trial
Official title:
A Randomized, Single-Blinded, Comparative Crossover Trial of the Safety and Efficacy of a Non-Invasive Targeted Electronic Pain Control Device ("Biowave System") Versus Transcutaneous Electrical Nerve Stimulation (TENS) for the Symptomatic Treatment of Chronic Low Back Pain.
Low back pain is a common condition, which extols a large cost to society from lost wages
The Biowave System was developed by Biowave Corporation (Biowave), Norwalk, CT. Two wires
emanate from the unit. The feed wire is attached to a large disposable input pad ("Feed
Electrode"). The return wire is attached to a smaller pad ("Return Electrode") over the
source of the pain (the treatment site).
The device sends a premixed modulated envelope of two high frequency electronic wave forms
("Feed Signal") between the two electrodes. The beat frequency of the modulated envelope
("d-Frequency") is equal to the difference in frequency of the two feed signals. The
location of beat frequency formation is dependent on the size and location of the two
electrodes. With the configuration used in the study, the beat frequency signal is believed
to form immediately ventrally to the Return electrode. The size of the volume of tissue
affected can be changed and is dependent upon electrode geometry and the amplitude of the
Feed Signal. The beat frequency is a low frequency blocking signal which is believed to
cause a demodulation in the nerve cells and a reduction of the sodium/potassium ion
exchange. As a result, the charge polarity of the nerve cell wall is prevented from changing
and is therefore unable to transmit pain impulses. The size of the volume of tissue affected
can be changed and is dependent upon electrode geometry and the amplitude of the Feed
Signal.
The objective of this study is to compare the Biowave System with TENS (a currently
available treatment) and to further evaluate its efficacy for the relief of pain in patients
with chronic low back pain.
Background-Low back pain is a common, costly & often chronic condition, estimated to affect
85% of people in their lifetime. A form of electronic pain control currently in use is TENS.
Although the exact mechanism is not completely understood, it is proposed that its
effectiveness is based on the gate control theory. Biowave has developed new patentable
technology & a related device in the field of electromedicine. The device delivers a precise
electrical signal to a specific volume of tissue in the body, which blocks the transmission
of pain impulses.
Treatment Plan-Treatment will be initiated with device indicated by the order to which the
pt. was randomized. Pts. will be connected to one of two devices hidden from view by
application of two small round two-inch diameter electrodes to the lower back.
Baseline-A complete medical history & a physical examination will be performed. The pt. will
complete a BPI questionnaire & be randomized to one of two treatment orders: 1) Biowave
device followed by TENS device or 2) TENS device followed by Biowave Device. 2 treatment
sessions will be separated by at least 72 hours.
Treatment-Prior to each treatment session, pt. will complete initial VAS evaluations. Pt.'s
ROM will be assessed & vital signs will be obtained. Pts. will complete VAS & categorical
pain assessments at end of the 20 minute treatment period.
Post-treatment-Pts. will repeat ROM test after device has been turned off & electrodes
removed. VAS pain evaluations will be completed by the pt. at 30 & 60 minutes, vital signs &
patient global impression of change will be obtained at 60 minutes following discontinuation
of therapy. Pts. will be given VAS & categorical pain assessments to be completed at 4, 6,
12, 24 and 48 hours & 1 week after treatment (to be returned by mail/fax) to assess possible
long-term analgesic effects.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03243084 -
Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Completed |
NCT03162952 -
RAND Center of Excellence for the Study of Appropriateness of Care in CAM
|
||
Completed |
NCT03240146 -
Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain
|
N/A | |
Completed |
NCT05282589 -
Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients
|
N/A | |
Completed |
NCT03637998 -
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain
|
N/A | |
Recruiting |
NCT02289170 -
Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)
|
N/A | |
Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
Completed |
NCT02231554 -
Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT02063503 -
Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients
|
N/A | |
Completed |
NCT01704677 -
Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT01177241 -
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids
|
N/A | |
Completed |
NCT01177254 -
Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
|
N/A | |
Completed |
NCT01177280 -
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes
|
N/A | |
Completed |
NCT01490905 -
A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain
|
Phase 4 | |
Completed |
NCT00984815 -
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
|
Phase 3 | |
Completed |
NCT00763321 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00761150 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00767806 -
A Study for Patient With Chronic Low Back Pain
|
Phase 3 |